Showing 611-620 of 7527 results for "".
Take Your Reception Area to the Next Level
https://practicaldermatology.com/topics/practice-management/take-your-reception-area-to-the-next-level/23011/The next focus for your booming dermatology practice may be where you least expect. Here are simple steps to increase retail sales in your reception area.Getting to the Root of ACD
https://practicaldermatology.com/topics/atopic-dermatitis/getting-to-the-root-of-acd/20356/A practical approach to dermatitis in young and old.Avoiding Laser and Energy-Based Device Complications
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/avoiding-laser-and-energy-based-device-complications/20564/Knowing how to avoid and effectively manage potential complications is key to success.Stirring the Pot: Cannabinoids and Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/stirring-the-pot-cannabinoids-and-atopic-dermatitis/20565/Cannabinoids are a diverse group of compounds that may hold significant therapeutic capabilities applicable to many areas of medicine, including dermatology.Focusing on Patient Education in Atopic Dermatitis
https://practicaldermatology.com/topics/practice-management/focusing-on-patient-education-in-atopic-dermatitis/20661/Patients of all ages have atopic dermatitis, and they seek education and support from their dermatologists.Fillers for the Décolletage Area
https://practicaldermatology.com/topics/practice-management/fillers-for-the-dcolletage-area/21113/Fillers offer patients an alternative to device-based interventions for chest rejuvenation.o, MDPanel Supports ATX-101; Melanoma Metastasis Test
https://practicaldermatology.com/topics/practice-management/dermwiretv-panel-supports-atx-101-melanoma-metastasis-test/18959/An FDA Advisory Panel Backs Kythera's ATX-101 for (Submental Fullness) or Double Chin, and a new genetic analysis may enhance SLN Biopsy findings to identify melanoma metastasis.Plus, Dan Siegel, MD, Darrell Rigel, MD, and Neal Bhatia, MD discuss the AAD's proposed dues increase and @NewDermMD launc“Natural” Remedies for Eczema: Evidence for the Alternative?
https://practicaldermatology.com/topics/general-topics/natural-remedies-for-eczema-evidence-for-the-alternative/22936/Limited data suggest the possibility that some natural agents may be particularly useful in the treatment of atopic dermatitis.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuJournal Club: What's New in Pathogenesis and Treatment of Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-whats-new-in-pathogenesis-and-treatment-of-atopic-dermatitis/26247/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Jason E. Hawkes, MD, a dermatologist practicing in the Sacramento area, and a member of the Practical Dermatology Editorial Board, about the latest research on the pathogenesis of and treatment targets for atopic dermatitis (AD).